| 产品名称: | HCC1428 BL |
|---|---|
| 商品货号: | TS212049 |
| Organism: | Homo sapiens, human |
| Tissue: | peripheral blood |
| Cell Type: | B lymphoblast; Epstein-Barr virus (EBV) transforme |
| Product Format: | frozen |
| Morphology: | lymphoblast |
| Culture Properties: | suspension, multicell aggregates |
| Biosafety Level: | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease: | Carcinoma,Cancer,Cancer,Adenocarcinoma |
| Gender: | female |
| Ethnicity: | Caucasian, White |
| Applications: | HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. |
| Storage Conditions: | liquid nitrogen vapor phase |
| Derivation: | HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428. HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers. |
| Clinical Data: | HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428. HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. female Caucasian, White |
| Comments: | HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428. HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers. The homozygous deletion in the FHIT gene is retained in the lymphoblastoid line. There is a familial history of breast cancer (maternal grandmother). HCC1428, a metastatic breast adenocarcinoma cell line, is available as ATCC CRL-2327. |
| Complete Growth Medium: | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing: | Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 x 105 viable cells/mL. Maintain cultures at cell concentrations between 5 x 105 and 1.5 x 106 viable cells/mL. Medium Renewal:xa0Every 2 to 3 days |
| Cryopreservation: | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions: | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Name of Depositor: | AF Gazdar, AK Virmani |
| References: | Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768 Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |